A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Safety of a Bovine Thymus Nuclear Extract

NCT ID: NCT06795945

Last Updated: 2025-12-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-02-04
• Study Completion Date: 2025-11-24

Brief Summary

The goal of this trial is to find out if Thymus Nuclear Extract is safe and well-tolerated in healthy men and women by testing three different dose levels and comparing the results to a placebo.

Detailed Description

This is a 12 to 25 week study (if study participants are willing to follow up on study results) where participants are randomly assigned to groups and neither they nor the researchers know who receives Thymus Nuclear Extract or a placebo. The trial focuses on evaluating the safety of the extract in healthy adults by monitoring for adverse events and conducting safety assessments throughout the study.

Conditions

Immunology

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: HEALTH_SERVICES_RESEARCH
• Blinding Strategy: TRIPLE

Study Groups

TPG1

Thymus Nuclear Extract Dose 1

Group Type: ACTIVE_COMPARATOR

TPG1

Intervention Type: DIETARY_SUPPLEMENT

• Thymus Nuclear Extract Dose 1 (860 mg [2 tablets, 2x/day; total 4 tablets per day])
• Placebo (6 tablets, 2x/day; total 12 tablets per day)

TPG2

Thymus Nuclear Extract Dose 2

Group Type: ACTIVE_COMPARATOR

TPG2

Intervention Type: DIETARY_SUPPLEMENT

• Thymus Nuclear Extract Dose 2 (2150 mg [5 tablets, 2x/day; total 10 tablets per day])
• Placebo (3 tablets, 2x/day; total 6 tablets per day)

TPG3

Thymus Nuclear Extract Dose 3

Group Type: ACTIVE_COMPARATOR

TPG3

Intervention Type: DIETARY_SUPPLEMENT

Thymus Nuclear Extract Dose 3 (3440 mg \[8 tablets, 2x/day; total 16 tablets per day\])

PL

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DIETARY_SUPPLEMENT

Placebo (8 tablets, 2x/day; total 16 tablets per day)

Interventions

TPG1

• Thymus Nuclear Extract Dose 1 (860 mg [2 tablets, 2x/day; total 4 tablets per day])
• Placebo (6 tablets, 2x/day; total 12 tablets per day)

Intervention Type: DIETARY_SUPPLEMENT

TPG2

• Thymus Nuclear Extract Dose 2 (2150 mg [5 tablets, 2x/day; total 10 tablets per day])
• Placebo (3 tablets, 2x/day; total 6 tablets per day)

Intervention Type: DIETARY_SUPPLEMENT

TPG3

Thymus Nuclear Extract Dose 3 (3440 mg \[8 tablets, 2x/day; total 16 tablets per day\])

Intervention Type: DIETARY_SUPPLEMENT

Placebo

Placebo (8 tablets, 2x/day; total 16 tablets per day)

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

1. Male and female participants who are between 18 - 65 years of age (inclusive).

2. In good general health (i.e., no uncontrolled diseases or conditions) as deemed by the investigator and are able to consume the study product.

3. Have a body mass index (BMI) range of 18.5 - 29.9 kg/m2 (inclusive).

4. Agree to follow the restrictions on concomitant treatments as listed.

5. Agree to use acceptable contraceptive methods as listed.

6. Willing and able to agree to the requirements of this study, be willing to give voluntary consent, be able to understand and read the questionnaires, and carry out all study-related procedures.

7. Agree to the dosage instructions including the oral consumption of 8 tablets twice daily.

Exclusion Criteria

1. Individuals who are lactating, pregnant or planning to become pregnant during the study, or demonstrates a positive pregnancy test at Visit 2.

2. Have a known sensitivity, intolerability, or allergy (especially to bovine products) to any of the study products or their excipients.

3. Have Type I diabetes, uncontrolled Type II diabetes, uncontrolled high blood pressure (≥140 systolic or ≥90 diastolic mmHg), or uncontrolled thyroid disease ("uncontrolled" defined as being unmedicated, have an unstable use of medication within 3 months prior to screening, or have a stable use of medication for 3 months but still have uncontrolled conditions).

4. Have a chronic inflammatory condition (e.g., rheumatoid arthritis, lupus, or multiple-sclerosis).

5. Have a neurological disorder which may impact cognitive testing (e.g., traumatic brain injury, epilepsy, neurodegenerative diseases).

6. Have received an organ transplant or other forms of allografts or xenografts.

7. Participants with sleep disorders (e.g., insomnia, sleep apnea, restless legs syndrome, narcolepsy, or any other condition that significantly affects sleep quality and duration)

8. Have medical condition(s) known to interfere with absorption, distribution, metabolism, or excretion of the study product (e.g., Crohn's disease, short bowel, acute or chronic pancreatitis, or pancreatic insufficiency).

9. Have a history of heart/cardiovascular disease, renal disease (dialysis or renal failure), hepatic impairment/disease, immune disorders and/or immunocompromised (i.e., HIV/AIDS).

10. Have a history of cancer (except localized skin cancer without metastases or in situ cervical cancer), unless recovery occurred more than 5 years before the screening visit.

11. Are receiving treatments for or have been hospitalized in the last 12 months for psychiatric disorders (e.g., depression, bipolar disorder, schizophrenia, etc.).

12. Reports a clinically significant illness during the 28 days before the first dose of study product.

13. Major surgery in 3 months prior to screening or planned major surgery during the study.

14. Have a history of alcohol or substance abuse in the 12 months prior to screening (including having been hospitalized for such in an in-patient or out-patient intervention program) or use that in the opinion of the investigator may be of a concern for the study.

15. Current enrollment or past participation in another study with any product(s) with at least one active ingredient within 28 days before first dose of study product or longer, if the previous test product is deemed by the investigator to have lasting effects that might influence the eligibility criteria or outcomes of current study.

16. Any other medical condition/situation or use of medications/supplements/therapies that, in the opinion of the investigator, may adversely affect the participant's ability to participate in the study or its measures or pose a significant risk to the participant.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Standard Process Inc.

INDUSTRY

Sponsor Role: lead

Nutrasource Pharmaceutical and Nutraceutical Services, Inc.

NETWORK

Sponsor Role: collaborator

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Bassem F. El-Khodor, PHD

Role: STUDY_DIRECTOR

Standard Process Inc.

Locations

Model Research Center

Tampa, Florida, United States

Countries

United States

Other Identifiers

S01-24-01-T0071

Identifier Type: -

Identifier Source: org_study_id